Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

The purpose of this study is to assess the safety and efficacy of an investigational nasal aerosol at two doses compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis in children (6-11 years of age).

• Drug: BDP nasal aerosol - 80 microgram dose once daily
  Participants/parents will administer 40 micrograms BDP HFA (one spray per nostril) per day for 15 days of treatment period
• Drug: BDP nasal aerosol - 160 microgram dose once daily
  Participants/parents will administer 80 micrograms BDP HFA per nostril per day for 15 days of treatment period
• Drug: Placebo Nasal Aerosol
  Participants/parents will administer placebo (no medication) spray HFA (one spray per nostril) per day for 15 days of treatment period

• Experimental: 80 micrograms once daily
  Participants/parents will administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) per day for 15 days of treatment period
  Intervention: Drug: BDP nasal aerosol - 80 microgram dose once daily
• Experimental: 160 micrograms once daily
  Participants/parents will administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) per day for 15 days of treatment period
  Intervention: Drug: BDP nasal aerosol - 160 microgram dose once daily
• Placebo Comparator: Placebo once daily
  Participants/parents will administer placebo (a spray with no medication) per nostril per day for 15 days of treatment period
  Intervention: Drug: Placebo Nasal Aerosol

Inclusion Criteria:

• Male or female subjects 6 to 11 years of age, as of the Screening Visit (SV)
• A documented history of SAR to a relevant seasonal allergen (tree/grass pollen) for a minimum of two years immediately preceding the study Screening Visit (SV).
• A demonstrated sensitivity to at least one seasonal allergen (tree/grass pollen) known to induce SAR through a standard skin prick test.
• Other criteria apply

Exclusion Criteria:

• History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the Screening Visit [SV])
• History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis or influenza,) within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-in Period.
• Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable
• Have any conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial
• Other criteria apply